Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4568096 | 0.91 | MDM4 (0.42) | KIF11PPARGBRD4MDM4MDM2 | |
| SCHEMBL3703087 | 0.91 | GPR17 (0.41) | PPARGBRD4GPR17 | |
| SCHEMBL3701174 | 0.87 | MDM4 (0.51) | MDM4MDM2 | |
| SCHEMBL15998649 | 0.86 | KDM4E (0.40) | — | |
| SCHEMBL4568540 | 0.86 | GPR17 (0.41) | PPARGGPR17 | |
| SCHEMBL3708494 | 0.85 | TUBB4A (0.50) | — | |
| SCHEMBL4568206 | 0.85 | TUBB4A (0.43) | — | |
| SCHEMBL4568560 | 0.85 | TUBB4A (0.43) | GPR17 | |
| SCHEMBL3703916 | 0.85 | PTGER1 (0.44) | — | |
| SCHEMBL3702535 | 0.84 | TUBB4A (0.48) | PPARGGPR17MDM4MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104151292-A | Indole derivative or pharmaceutically acceptable salt thereof | KISSEI PHARMACEUTICAL | 2014-11-19 | — | — | CN | claimed |
| CN-104151292-A | Indole derivative or pharmaceutically acceptable salt thereof | KISSEI PHARMACEUTICAL | 2014-11-19 | — | — | CN | disclosed |
| EP-2474530-A1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | KIF11 3272/4885PPARG 500/4885BRD4 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.